ERBB2 and neoplasm: Peng et al. reported the preparation of a dual-targeted liposome system for the delivery of vorinostat and gefitinib that is decorated with the anti-HER-2 antibody and mannose for targeting HER-2-overexpressing tumor cells and mannose receptor-expressed tumor-associated macrophages (TAMs), respectively.